L
Leonardo Patruno
Researcher at University of L'Aquila
Publications - 6
Citations - 138
Leonardo Patruno is an academic researcher from University of L'Aquila. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 2, co-authored 3 publications receiving 50 citations.
Papers
More filters
Journal ArticleDOI
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
Sebastiano Buti,Melissa Bersanelli,Fabiana Perrone,Marcello Tiseo,Marco Tucci,Vincenzo Adamo,Luigia Stefania Stucci,Alessandro Russo,Enrica Teresa Tanda,Francesco Spagnolo,Francesca Rastelli,Federica Pergolesi,Daniele Santini,Marco Russano,Cecilia Anesi,Raffaele Giusti,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Alain Gelibter,Mario Occhipinti,Marco Ferrari,Maria Giuseppa Vitale,Linda Nicolardi,Rita Chiari,Erika Rijavec,Olga Nigro,Alessandro Tuzi,Michele De Tursi,Pietro Di Marino,Fabio Conforti,Paola Queirolo,Sergio Bracarda,Serena Macrini,Stefania Gori,Federica Zoratto,Enzo Veltri,Barbara Di Cocco,Domenico Mallardo,Maria Grazia Vitale,Matteo Santoni,Leonardo Patruno,Giampiero Porzio,Corrado Ficorella,David J. Pinato,Paolo A. Ascierto,Alessio Cortellini +46 more
TL;DR: Cumulative exposure to corticosteroids, antibiotics and PPIs (three likely microbiota-modulating drugs) leads to progressively worse outcomes after ICI therapy, and a simple prognostic score is proposed that can help stratifying patients in routine practice and clinical trials of ICIs.
Journal ArticleDOI
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
Alessio Cortellini,Federico Bozzetti,Pierpaolo Palumbo,Davide Brocco,Pietro Di Marino,Nicola Tinari,Michele De Tursi,Veronica Agostinelli,Leonardo Patruno,Cristina Valdesi,Manuela Mereu,Lucilla Verna,Paola Lanfiuti Baldi,Olga Venditti,Katia Cannita,Carlo Masciocchi,Antonio Barile,Jennifer L. McQuade,Corrado Ficorella,Giampiero Porzio +19 more
TL;DR: Low SMI is associated with shortened survival in advanced cancer patients treated with PD1/PDL1 checkpoint inhibitors and the lack of an association between SMI and clinical response suggests that sarcopenia may be generally prognostic in this setting rather than specifically predictive of response to immunotherapy.
Journal ArticleDOI
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
Alessandro Parisi,Alessio Cortellini,Alessio Cortellini,Olga Venditti,Roberto Filippi,Lisa Salvatore,Lisa Salvatore,Giampaolo Tortora,Giampaolo Tortora,Michele Ghidini,Olga Nigro,Fabio Gelsomino,Ina Valeria Zurlo,Claudia Angela Maria Fulgenzi,Pasquale Lombardi,Susana Rosello Keranen,Susana Rosello Keranen,Ilaria Depetris,Riccardo Giampieri,Cristina Morelli,Pietro Di Marino,Francesca Di Pietro,N. Zanaletti,P. Vitale,Ingrid Garajová,Gian Paolo Spinelli,Federica Zoratto,Michela Roberto,Angelica Petrillo,Giacomo Aimar,Leonardo Patruno,Carla D'Orazio,Corrado Ficorella,Claudio Ferri,Giampiero Porzio +34 more
TL;DR: In this article, the authors evaluated post-induction management following first-line anti-epidermal growth factor receptor (EGFR)-based doublet regimens in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC).
Journal ArticleDOI
Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
Veronica Zelli,Alessandro Parisi,Leonardo Patruno,Katia Cannita,Corrado Ficorella,Carla Luzi,Chiara Compagnoni,Francesca Zazzeroni,Edoardo Alesse,Alessandra Tessitore +9 more
TL;DR: Overall, this study case series adds evidence to the limited available literature concerning both the epidemiological and clinical aspects of CRC cases characterized by the presence of concurrent RAS/BRAF variants.
Journal ArticleDOI
Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy
Azzurra Irelli,Sofia Chiatamone Ranieri,Daniela Di Giacomo,Sara Malatesta,Leonardo Patruno,Alessandra Tessitore,Edoardo Alesse,Katia Cannita +7 more
TL;DR: In this paper , the role of molecular tumor boards (MTBs) in the management of patients with metastatic breast cancer (MBC) is analyzed, and it is suggested to include patients in molecular screening programs in order to be able to offer targeted therapies for specific genomic alterations.